Home » Conference Coverage » American Society of Pediatric Hematology/Oncology » ASPHO 2022
ASPHO 2022
Researchers sought to determine the effect of transplant-related complications and socioeconomic factors on revaccination schedule adherence among pediatric patients following allo-HSCT.
Researchers sought to determine whether tisagenlecleucel is safe and effective in patients younger than 3 years old with relapsed/refractory ALL.
Researchers sought to evaluate the effect of the CDC’s guideline on opioid prescriptions and health outcomes on patients with SCD.
Researchers sought to determine whether monitoring SAA levels would be a helpful strategy for determining therapy efficacy in infants with ALL.
Researchers sought to determine whether emicizumab would be safe and effective in pediatric patients with hemophilia A with FVIII inhibitors.
Load More
Open
Next post in ASPHO 2022
Close
Close more info about Delays in Initiation of Revaccination in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant
Loading...
Close more info about Delays in Initiation of Revaccination in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant
Loading...